Jennifer Smit is a Vice President and Compound Development Leader at Johnson & Johnson, where they currently lead the Janssen multiple myeloma CD3 redirector programs. They have extensive pharmaceutical experience in drug development, previously serving as the Compound Development Team Leader for Imbruvica and holding a Director role in Project Management. Jennifer has a strong background in process improvement, compliance, and global product registrations, alongside a passion for coaching and team development. They are also an Adjunct Professor at Thomas Jefferson University and are pursuing a Bachelor of Science in Biochemistry and Molecular Biology at Rutgers University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices